Cannabidiol Inhibits Epithelial Ovarian Cancer: Role of Gut Microbiome

• DOI: 10.1021/acs.jnatprod.3c00782
• Publication Date: 2024-04-11T18:58:45Z
• Authors: Danli Cao; Yiru Lin; Caiji Lin; Mengzhi Xu; Jiaxing Wang; Zheng Zeng; Pengfei Wang; Qinghai Li; Xiaoyu Wang; Wenxue Wang; Lingjie Luo; Yufan Zhao; Yongwei Shi; Zixiang Gao; Xin Kang; Shuang Wang; Yuanyuan Zhang; Xiaohui Xu; Shu-Lin Liu; Huidi Liu

Epithelial ovarian cancer is among the deadliest gynecological tumors worldwide. Clinical treatment usually consists of surgery and adjuvant chemo- radiotherapies. Due to high rate recurrence rapid development drug resistance, current focus research on finding effective natural products with minimal toxic side effects for treating epithelial tumors. Cannabidiol most abundant cannabinoids has a non-psychoactive effect compared tetrahydrocannabinol, which key advantage clinical application. Studies have shown that cannabidiol antiproliferative, pro-apoptotic, cytotoxic, antiangiogenic, anti-inflammatory, immunomodulatory properties. However, its therapeutic value remains unclear. This study aims investigate elucidate underlying mechanisms. The results showed significant inhibitory In vivo experiments demonstrated could inhibit tumor growth by modulating intestinal microbiome increasing abundance beneficial bacteria. Western blot assays bound EGFR/AKT/MMPs proteins suppressed expression in dose-dependent manner. Network pharmacology molecular docking suggested affect signaling pathway.